FP14.11 Icotinib versus Chemotherapy as Adjuvant Treatment for Stage II–IIIA EGFR-Mutant NSCLC (EVIDENCE): A Randomized, Open-Label, Phase 3 StudyCaicun Zhou, Li Mao, Shidong Xu et al.|Journal of Thoracic Oncology|2021Cited by 5
Mechanism exploration and biomarker identification of glycemic deterioration in patients with diseases of the exocrine pancreasZhen Wang, Lin Zhang, Guolin Zhang et al.|Scientific Reports|2024Cited by 0